Biomedicines, Vol. 12, Pages 2865: Maresin-like 1 Ameliorates Neuropathology of Alzheimer’s Disease in Brains of a Transgenic Mouse Model

Biomedicines, Vol. 12, Pages 2865: Maresin-like 1 Ameliorates Neuropathology of Alzheimer’s Disease in Brains of a Transgenic Mouse Model

Biomedicines doi: 10.3390/biomedicines12122865

Authors: Pallavi Shrivastava Yan Lu Shanchun Su Yuichi Kobayashi Yuhai Zhao Nathan Lien Abdul-Razak Masoud Walter J. Lukiw Song Hong

(1) Background: Impeded resolution of inflammation contributes substantially to the pathogenesis of Alzheimer’s disease (AD); consequently, resolving inflammation is pivotal to the amelioration of AD pathology. This can potentially be achieved by the treatment with specialized pro-resolving lipid mediators (SPMs), which should resolve neuroinflammation in brains. (2) Methods: Here, we report the histological effects of long-term treatment with an SPM, maresin-like 1 (MarL1), on AD pathogenesis in a transgenic 5xFAD mouse model. (3) Results: MarL1 treatment reduced Aβ overload, curbed the loss of neurons in brains especially cholinergic neurons associated with cleaved-caspase-3-associated apoptotic degeneration, reduced microgliosis and the pro-inflammatory M1 polarization of microglia, curbed the AD-associated decline in anti-inflammatory Iba1+Arg-1+-M2 microglia, inhibited phenotypic switching to pro-inflammatory N1 neutrophils, promoted the blood–brain barrier-associated tight-junction protein claudin-5 and decreased neutrophil leakage in 5xFAD brains, and induced the switch of neutrophils toward the inflammation-resolving N2 phenotype. (4) Conclusions: Long-term administration of MarL1 mitigates AD-related neuropathogenesis in brains by curbing neuroinflammation and neurodegeneration, based on the histological results. These findings provide preclinical leads and mechanistic insights for the development of MarL1 into an effective modality to ameliorate AD pathogenesis.